Business Wire

Sulzer: New Disposable Application System for 2-K Materials

16.3.2017 13:00 | Business Wire


Sulzer will unveil a brand new product at IDS 2017 in Cologne: the Unit Dose 0.5ml, a single-use hygienic application system for two-component materials that saves time and is simple to use.

This Smart News Release features multimedia. View the full release here:

The new single-use Unit Dose 0.5ml is a hygienic application system for two-component materials. Ima ...

The new single-use Unit Dose 0.5ml is a hygienic application system for two-component materials. Image source: Sulzer Mixpac, may be used free of charge. (Photo: Business Wire)

Sulzer Mixpac AG – a subsidiary of Sulzer Ltd., a global leader in the manufacture and supply of liquid application and mixing technology products and services – will showcase the new Unit Dose 0.5ml at IDS in Cologne from 21-25 March 2017. The disposable application system is designed for use with two-component dental materials such as cements or bleaching materials. “The Unit Dose 0.5ml simplifies the application of cements and saves time, which in turn improves hygiene and safety”, explains Martina Strasser, Head of Sales Dental.

Easy to use and reliable mixing results

The ergonomically designed Unit Dose 0.5ml is simple to use and has a range of safety features, such as transport protection and a safety fastener. “It is very economical as there is no unnecessary material wastage thanks to the integrated MIXPACTM T-Mixer mixing technology. This new product guarantees reliable, high-quality mixing results and prevents cross-contamination,” says Hanspeter Benz, Product Manager Dental. Clear visual indicators ensure that the user can see at a glance whether the system has been activated and is ready to use.

Another innovation for 2017: Sulzer MIXPAC TM T-Mixer Colibri

An additional innovation recently launched by Mixpac is the T-Mixer™ Colibri mixing tip, which was showcased in autumn at GNYDM in New York and then at CIOSP in São Paulo. The T-Mixer Colibri featuring an integrated 180° bendable cannula that can be rotated 360° for the precise application and mixing of multi-component dental materials, has been specially designed for use in root canal work and cementation. The economical T-Mixer Colibri™ ingeniously combines two of Mixpac’s most successful products. It couples the geometry of the reliable T-Mixer™ with all the advantages of the bendable Colibri™ application cannula. The mixing tip allows for an ergonomic posture and highly professional work, even when treating areas that are difficult to reach, meaning that changes to the working environment are not necessary. Due to its short, compact design the T-Mixer Colibri also uses up to 40 percent less material compared to helix mixing tips. The result is a consistent, homogenous application – even when bent – thanks to the uniform internal diameter of the gently curved stainless steel medical cannula.

Sulzer Mixpac: strong focus on service and R&D

Sulzer works with leading international manufacturers of materials and opinion leaders in the dental industry to develop new forms of application and custom products. With the help of the experts at the company’s own application laboratory, and at little expense, customers and partners receive help in identifying the application technology best suited to the materials they use. The mixing and application systems manufacturer takes responsibility for implementing product ideas, as well as tooling and innovative packaging options. Sulzer provides customers with on-site service through its close-knit network of distribution partners.

Sulzer Mixpac at IDS 2017

Koelnmesse, Messeplatz 1, 50679 Cologne

Stand B41, hall 3.2

Press kit

Contact information

Samuel Fitzi
Marketing Project Manager Dental, Sulzer Mixpac AG
Tel: +41 (0)81 7722177

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati

Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11Pressemelding

Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom